Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR

Circulation1 Dec 2018Cited by 110 (Europe PMC)

PMID30566006PMCIDPMC6296845DOI10.1161/circulationaha.118.036418PepBankPUB-30566006

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR of 60 or higher, liraglutide did not significantly change the primary composite cardiovascular outcome versus placebo (hazard ratio 0.94).
In plain wordsIn people with type 2 diabetes and eGFR of 60 or higher, liraglutide did not clearly change major heart and stroke events versus placebo.
Peptide
Liraglutide
Outcome
No significant changePrimary composite cardiovascular outcome, eGFR 60 or higher
Study
n = 7,182
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.94
eGFR >=60
Source sentences
Summary
In patients with eGFR 2, risk reduction for the primary composite cardiovascular outcome with liraglutide was greater (hazard ratio [HR], 0.69; 95% CI, 0.57-0.85) versus those with eGFR ≥60 mL/min/1.73 m² (HR, 0.94; 95% CI, 0.83-1.07; interaction P=0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600602
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR below 60, liraglutide reduced the primary composite cardiovascular outcome versus placebo (hazard ratio 0.69).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, liraglutide led to fewer major heart and stroke events than placebo.
Peptide
Liraglutide
Outcome
DecreasePrimary composite cardiovascular outcome, eGFR <60
Study
n = 2,158
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.69
eGFR <60
Source sentences
Summary
In patients with eGFR 2, risk reduction for the primary composite cardiovascular outcome with liraglutide was greater (hazard ratio [HR], 0.69; 95% CI, 0.57-0.85) versus those with eGFR ≥60 mL/min/1.73 m² (HR, 0.94; 95% CI, 0.83-1.07; interaction P=0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600601
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the liraglutide effect on the primary cardiovascular outcome showed no consistent modification across finer eGFR subgroups or continuous eGFR.
In plain wordsIn adults with type 2 diabetes, the benefit of liraglutide did not change in a consistent way across kidney function levels.
Peptide
Liraglutide
Outcome
No significant changeEffect modification by eGFR subgroups and continuous eGFR
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
There was no consistent effect modification with liraglutide across finer eGFR subgroups (interaction P=0.13) and when analyzing eGFR as a continuous variable (interaction P=0.61).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and baseline albuminuria, liraglutide reduced the primary composite cardiovascular outcome versus placebo (hazard ratio 0.83).
In plain wordsIn adults with type 2 diabetes and protein in the urine, liraglutide led to fewer major heart and stroke events than placebo.
Peptide
Liraglutide
Outcome
DecreasePrimary composite cardiovascular outcome, with albuminuria
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.83
with albuminuria
Source sentences
Summary
Risk reduction for the primary composite cardiovascular outcome was not different for those with versus without baseline albuminuria (HR, 0.83; 95% CI, 0.71-0.97; and HR, 0.92; 95% CI, 0.79-1.07, respectively; interaction P=0.36).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600612
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and no baseline albuminuria, liraglutide did not significantly change the primary composite cardiovascular outcome versus placebo (hazard ratio 0.92); the risk reduction did not differ by albuminuria.
In plain wordsIn adults with type 2 diabetes and no protein in the urine, liraglutide did not clearly change major heart and stroke events compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePrimary composite cardiovascular outcome, without albuminuria
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.92
without albuminuria
Source sentences
Summary
Risk reduction for the primary composite cardiovascular outcome was not different for those with versus without baseline albuminuria (HR, 0.83; 95% CI, 0.71-0.97; and HR, 0.92; 95% CI, 0.79-1.07, respectively; interaction P=0.36).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600613
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR of 60 or higher, liraglutide did not significantly change nonfatal myocardial infarction versus placebo (hazard ratio 0.93).
In plain wordsIn people with type 2 diabetes and eGFR of 60 or higher, liraglutide did not clearly change non-fatal heart attacks versus placebo.
Peptide
Liraglutide
Outcome
No significant changeNonfatal myocardial infarction, eGFR 60 or higher
Study
n = 7,182
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.93
eGFR >=60
Source sentences
Summary
for nonfatal myocardial infarction, HR, 0.74; 95% CI, 0.55-0.99 versus HR, 0.93; 95% CI, 0.77-1.13
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600605
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR of 60 or higher, liraglutide did not significantly change nonfatal stroke versus placebo (hazard ratio 1.07).
In plain wordsIn people with type 2 diabetes and eGFR of 60 or higher, liraglutide did not clearly change non-fatal strokes versus placebo.
Peptide
Liraglutide
Outcome
No significant changeNonfatal stroke, eGFR 60 or higher
Study
n = 7,182
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
1.07
eGFR >=60
Source sentences
Summary
for nonfatal stroke, HR, 0.51; 95% CI, 0.33-0.80 versus HR, 1.07; 95% CI, 0.84-1.37
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600607
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR of 60 or higher, liraglutide did not significantly change cardiovascular death versus placebo (hazard ratio 0.84).
In plain wordsIn people with type 2 diabetes and eGFR of 60 or higher, liraglutide did not clearly change heart-related deaths versus placebo.
Peptide
Liraglutide
Outcome
No significant changeCardiovascular death, eGFR 60 or higher
Study
n = 7,182
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.84
eGFR >=60
Source sentences
Summary
for cardiovascular death, HR, 0.67; 95% CI, 0.50-0.90 versus HR, 0.84; 95% CI, 0.67-1.05
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600609
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR of 60 or higher, liraglutide did not significantly change all-cause mortality versus placebo (hazard ratio 0.90).
In plain wordsIn people with type 2 diabetes and eGFR of 60 or higher, liraglutide did not clearly change deaths from any cause versus placebo.
Peptide
Liraglutide
Outcome
No significant changeAll-cause mortality, eGFR 60 or higher
Study
n = 7,182
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.9
eGFR >=60
Source sentences
Summary
for all-cause mortality, HR, 0.74; 95% CI, 0.60-0.92 versus HR, 0.90; 95% CI, 0.75-1.07.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600611
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR below 60, liraglutide reduced nonfatal myocardial infarction versus placebo (hazard ratio 0.74).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, liraglutide led to fewer non-fatal heart attacks than placebo.
Peptide
Liraglutide
Outcome
DecreaseNonfatal myocardial infarction, eGFR <60
Study
n = 2,158
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.74
eGFR <60
Source sentences
Summary
for nonfatal myocardial infarction, HR, 0.74; 95% CI, 0.55-0.99 versus HR, 0.93; 95% CI, 0.77-1.13
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600604
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR below 60, liraglutide reduced nonfatal stroke versus placebo (hazard ratio 0.51).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, liraglutide led to fewer non-fatal strokes than placebo.
Peptide
Liraglutide
Outcome
DecreaseNonfatal stroke, eGFR <60
Study
n = 2,158
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.51
eGFR <60
Source sentences
Summary
for nonfatal stroke, HR, 0.51; 95% CI, 0.33-0.80 versus HR, 1.07; 95% CI, 0.84-1.37
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600606
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR below 60, liraglutide reduced cardiovascular death versus placebo (hazard ratio 0.67).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, liraglutide led to fewer deaths from heart and blood vessel causes than placebo.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular death, eGFR <60
Study
n = 2,158
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.67
eGFR <60
Source sentences
Summary
for cardiovascular death, HR, 0.67; 95% CI, 0.50-0.90 versus HR, 0.84; 95% CI, 0.67-1.05
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600608
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and eGFR below 60, liraglutide reduced all-cause mortality versus placebo (hazard ratio 0.74).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, liraglutide led to fewer deaths from any cause than placebo.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality, eGFR <60
Study
n = 2,158
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.74
eGFR <60
Source sentences
Summary
for all-cause mortality, HR, 0.74; 95% CI, 0.60-0.92 versus HR, 0.90; 95% CI, 0.75-1.07.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care.
Summary · context
These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; 2) and baseline albuminuria.
Report a problemFND-3056600610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.